Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across...

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR)-T cell therapies represent significant advancements in anti-cancer treatments, showing remarkable clinical outcomes in hematological malignancies.
• The growing importance of genetically engineered cellular therapies necessitates strategies to expedite their development and evidence generation.
• Optimizing the development pathway for next-generation cellular therapies can positively impact patient outcomes.

Purpose of the Study:

• To outline a risk-based methodology and assessment aid for data extrapolation across related genetically engineered cellular therapy products.
• To demonstrate the broad applicability of systematic data extrapolation beyond CAR-T cells for various immune therapies.
• To influence clinical development strategies for novel cell-based therapies.

Main Methods:

• A risk-based methodology and assessment aid for data extrapolation were developed.
• Commonalities in manufacturing processes, clinical trial designs, and regulatory considerations across related cellular therapies were analyzed.
• Key learnings were identified to support optimization of development and regulatory approval.

Main Results:

• The analysis identified key commonalities in manufacturing, clinical trials, and regulatory aspects of cellular therapies.
• These insights provide a foundation for optimizing the development and regulatory pathways for novel cell therapies.
• The data extrapolation approach was shown to be applicable to a wide range of immune therapies.

Conclusions:

• Cellular therapy offers immense promise for safe and effective cancer treatment.
• Data extrapolation across related products can streamline the development process for novel cellular therapies.
• Accelerating the delivery of innovative cellular therapies to patients is a key opportunity.